APA (7th ed.) Citation

Gennari, A., Nardin, S., Brain, E., Piccardo, A., De Censi, A., Matteucci, F., . . . Harbeck, N. (2025). 572P Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intrapatient heterogeneity in ER+/HER2- metastatic breast cancer (MBC) treated with first-line endocrine therapy: Final results of the ET-FES trial. Annals of Oncology, 36, S445. https://doi.org/10.1016/j.annonc.2025.08.994

Chicago Style (17th ed.) Citation

Gennari, A., et al. "572P Molecular Imaging with 18F-fluoroestradiol (18F-FES) to Assess Intrapatient Heterogeneity in ER+/HER2- Metastatic Breast Cancer (MBC) Treated with First-line Endocrine Therapy: Final Results of the ET-FES Trial." Annals of Oncology 36 (2025): S445. https://doi.org/10.1016/j.annonc.2025.08.994.

MLA (9th ed.) Citation

Gennari, A., et al. "572P Molecular Imaging with 18F-fluoroestradiol (18F-FES) to Assess Intrapatient Heterogeneity in ER+/HER2- Metastatic Breast Cancer (MBC) Treated with First-line Endocrine Therapy: Final Results of the ET-FES Trial." Annals of Oncology, vol. 36, 2025, p. S445, https://doi.org/10.1016/j.annonc.2025.08.994.